Default company panoramic image
4e2c2c92 1742 4235 8792 8945881de548


Celltana has developed novel and proprietary laboratory growth media and cell lines that will transform cancer R&D and patient treatment.

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Miami, FL, USA
  • Currency USD
  • Employees 2

Company Summary

Pharmaceutical R&D in cancer has traditionally been limited by the inability to grow and test human tumors in the laboratory. Celltana's proprietary growth media and cell lines fill this unmet need. Our goal is to transform drug development by providing a real-time platform for pharma companies to test novel drugs, and optimize treatment for patients by enabling doctors to identify the best drug to treat the patient's specific cancer.


  • Default avatar
    Michael C Cerio
    President and CEO

    Michael Cerio, M.B.A., M.S. is President and CEO of Celltana. Previously he was President and CEO of Oncolome Diagnostics, an oncology diagnostics company he founded to develop and commercialize molecular diagnostics for cancer. He also served as interim CEO of Modulation Therapeutics, an early stage company focused on development of novel drugs for multiple myeloma. From 2005 – 2011 Mr.Cerio was Senior Director of Business Development for Gen

  • Default avatar
    Tan Ince
    Executive Vice President and CSO

    Tan Ince, M.D., Ph.D. is Executive Vice President and CSO of Celltana, and the inventor of the company’s foundational technologies. Dr. Ince is also Associate Professor of Pathology and director of the Tumor Stem Cell Division at the Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine. After receiving his MD at Hacettepe University in Ankara, Dr. Ince received a PhD degree in Pharmacology from Cornell University.


  • Default avatar
    Foley & Lardner, LLP (Curt Creely, Esq.)